NLS Pharma News

CDMO – September 24, 2025

PolyPeptide Group achieves milestone in Malmö expansion

PolyPeptide Group has announced the successful delivery and installation of pre-built modules at its Malmö, Sweden facility.

Acquisition – September 22, 2025

Kancera to seek stakeholders for a reverse take over

The company’s board has decided to initiate a process to seek potential stakeholders for a reverse take over of the company with the aim to materialize the value of its public listing.

Pharma Business – September 22, 2025

Sobi’s Tryngolza approved in the EU for familial chylomicronemia syndrome

Sobi and Ionis Pharmaceuticals have announced that Tryngolza (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS).

Pharma Business – September 17, 2025

EU approval of updated label of Novo Nordisk’s oral semaglutide

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.

Agreement – September 17, 2025

ALK enters partnership with GenSci

ALK has announced a partnership agreement with China-based Changchun GeneScience Pharmaceutical to develop and commercialize ALK’s house dust mite allergy immunotherapy (AIT) products in Mainland China.

Clinical Trials

Clinical Trials – September 24, 2025

New study aims to provide more cancer patients with targeted treatments

The new, national study uses genetic analysis of tumors to match cancer patients with targeted drugs – even when these are not yet approved for their specific diagnosis.

Clinical Trials – September 17, 2025

AnaCardio completes target enrollment in Phase 2a study

AnaCardio has announced that its ongoing Phase 2a study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF) is fully enrolled and remains on track to report results by year-end 2025.

Clinical Trials – September 15, 2025

Cinclus Pharma screens first patient in Phase III trial

The first patient has been screened in the company’s HEEALING 1 Phase III trial evaluating linaprazan glurate for the treatment of erosive gastroesophageal reflux disease (GERD).

Clinical Trials – September 8, 2025

Orexo announces positive in vivo data

The company has announced pharmacokinetic in-vivo data for a powder-based intranasal semaglutide formulation developed with the AmorphOX technology.

Clinical Trials – September 1, 2025

SweTrial is a reality

The government decided in the end of July 2025 to establish the SweTrial partnership, an initiative aimed to strengthen Sweden’s role as a life science nation and make it easier to conduct clinical trials in the country.

Clinical Trials – August 27, 2025

Active lymphoma eliminated in 4 out of 6 patients in Elicera’s CARMA study

Elicera Therapeutics has announced preliminary data from the first two cohorts of the ongoing Phase I/IIa CARMA study with ELC-301.

Clinical Trials – August 4, 2025

Hansa Biopharma announces new supportive trial data

The company has announced topline results from three patients with Duchenne muscular dystrophy (DMD) treated with Hansa’s imlifidase prior to receiving Sarepta’s ELEVIDYS in the SRP-9001-104 trial.

Clinical Trials – June 19, 2025

BioArctic to initiate next cohorts in Phase 2a study

The interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated.

Clinical Trials – June 18, 2025

Kancera reports positive top-line results

The company has announced results from the KANDOVA study, a one-arm, open-label, multi-centre combined phase Ib/IIa study of KAND567 in combination with carboplatin in ovarian cancer.

Clinical Trials – June 18, 2025

Abera announces new study results

The company has presented results from a recently completed study that further demonstrates the potential of its vaccine platform for pandemic preparedness.

Profiles in Pharma

Profiles in Pharma – April 2, 2025

The Jalkanens: A shared thirst for knowledge

For Sirpa and Markku Jalkanen of Finland, M.D. and Ph.D., married, immunotherapy researchers, working together came as naturally as a courtship.

Profiles in Pharma – November 1, 2023

Jonina Gudmundsdottir, Coripharma

In the heart of Iceland’s life sciences industry, Jonina Gudmundsdottir, the CEO of Coripharma, is making her mark. With a deep understanding of the industry’s challenges and a relentless drive for excellence, Gudmundsdottir has steered Coripharma toward transformative success. Iceland’s life sciences industry has thrived in recent years, propelled by its unique strengths. With a […]

Profiles in Pharma – July 3, 2023

Deborah Dunsire

The CEO of Lundbeck, who announced that she will retire last week, did not initially intend to join the life science industry, but it captivated her more than 30 years ago, and the ability to transform lives still drives her to this day. For more than 100 years, Lundbeck has been at the forefront of […]

Profiles in Pharma – October 1, 2021

Malin Parkler – Passionate about science, health & leadership

Malin Parkler, CEO of Pfizer Sweden, is driven by curiosity and a passion to build knowledge and evolve the life science industry – with the ultimate goal to yield real benefits for patients. Rarely has the world been more in need of leaders. As the global community struggled with the COVID-19 pandemic last year, people […]

Profiles in Pharma – August 15, 2019

Katarina Ageborg, CEO AstraZeneca Sweden

Few companies are as synonymous with Sweden as AstraZeneca and few CEOs as visible. Yet, Katarina Ageborg, AstraZeneca Sweden’s new CEO, prefers not to think about being center stage, but instead about what her position can do for the company, Sweden and the pharmaceutical industry as a whole. “I don’t think about it that way […]

Profiles in Pharma – July 1, 2017

Embracing diversity – for the sake of true innovation

Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief in the need for diversity to truly bring forth innovation. A view that is also deeply incorporated in her job as Head of MedImmune. Editor’s note: In 2019 Bahika Jallal left MedImmune and became the […]

Profiles in Pharma – March 22, 2017

“The scientist in me wants to make a difference”

After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further to start something on her own. As founder and CEO of PILA PHARMA she hopes to bring a new oral anti-diabetic agent to the market. What made you take the leap to go on your […]

Profiles in Pharma – March 8, 2017

“We have to embrace the new era of diabetes care”

Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development strategy, the new era of diabetes care and his 25 year-long passion for his job. The changing diabetes market, with increasing competition and high prices for diabetes products in the US, has made the world’s […]

Profiles in Pharma – February 16, 2017

From regulator to pharma industry specialist

Dr. Thomas Lönngren, former head of the EMA and today a pharmaceutical consultant, provides some insights on the aftermath of Brexit, describes current challenges the industry is facing and takes a short walk down memory lane on his career journey. The summer of 2016 will be remembered for many things; record temperatures, terrorist acts in […]

Profiles in Pharma – April 21, 2014

Jan Lundberg: The long view of R&D at Eli Lilly

Like sports, R&D requires team spirit, commitment, and a long view says Dr. Jan Lundberg, Lilly executive vice president for science and technology, and president of Lilly Research Laboratories. Dr. Jan Lundberg’s online bios and YouTube videos portray a steely pharmaceutical executive whose idea of fun is a 90 km ski race. It’s all true. […]